论文部分内容阅读
目的 探讨卵巢癌抗原-125（CA125）的测定对卵巢癌的诊断及预后的临床价值。方法 采用ELISA法测定124例患者治疗前后的血清CA125（卵巢癌19例、子宫肌瘤34例、卵巢良性畸胎瘤29例及其它妇科疾病42例）。结果 卵巢癌阳性率94.7%（18/19），子宫肌瘤、卵巢良性畸胎瘤及其它妇科疾病的阳性率分别为17.6%(6/34)、24%（7/29）和14.35%（6/42）。19例卵巢癌患者经化疗或手术治疗后有14例血清CA125含量显著下降，其余良性妇科疾病经治疗后虽然有不同程度的降低，但降低幅度不大。 结论 血清CA125测定对卵巢癌的诊断及预后有较高的临床价值。
Objective To investigate the clinical value of ovarian cancer antigen-125 (CA125) in the diagnosis and prognosis of ovarian cancer. Methods Serum CA125 (19 ovarian cancer, 34 myoma of uterus, 29 benign ovarian teratoma and 42 other gynecological diseases) before and after treatment were measured by ELISA. Results The positive rates of ovarian cancer were 94.7% (18/19), 17.6% (6/34), 24% (7/29) and 14.35% (17/29) respectively for uterine fibroids, benign ovarian teratomas and other gynecological diseases 6/42). 19 cases of ovarian cancer patients after chemotherapy or surgical treatment of 14 cases of serum CA125 levels decreased significantly, while the rest of the benign gynecological diseases after treatment, although with varying degrees of reduction, but the decrease was not. Conclusion Serum CA125 has high clinical value in the diagnosis and prognosis of ovarian cancer.